Study guide
3.9 Carrier, Somatic & Research Testing
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
3.9 Carrier, Somatic & Research Testing
Key Takeaways Explain This Topic AI
Carrier screening identifies heterozygotes for recessive (and sometimes X-linked) conditions to inform reproductive risk; it does not diagnose disease in typically asymptomatic carriers.
Practice has shifted from ethnicity-based panels toward more universal/expanded offering, while still using ancestry history to refine residual risk and targeted conditions when relevant.
Somatic tumor testing detects variants in tumor tissue to guide oncology treatment; germline confirmation is needed when findings may be constitutional or have family implications.
Research genetic testing follows protocol/IRB rules and may lack clinical-grade interpretation or guaranteed return of results; it is not a substitute for indicated clinical testing.
Consent must match the test type: reproductive carrier implications, tumor-vs-germline distinctions, and research limitations including uncertain result-return policies.
Last updated: August 2026
Carrier testing and carrier screening
Carrier testing usually means testing an individual for carrier status—often because a partner is a known carrier, a family history exists, or an ethnicity/ancestry risk is recognized. Carrier screening is the broader offer of testing to people without a known familial variant, typically preconception or prenatal, to identify reproductive risks for autosomal recessive and selected X-linked conditions.
- Feature Carrier screening/testing Diagnostic testing
- Usual phenotype of consultand Unaffected Affected
Primary question Could I pass a condition to offspring? Do I have this disease genetically?
- Positive result meaning Heterozygote (usually); reproductive risk rises if partner also carries
- Negative result meaning Residual risk remains (assay doesn’t detect all variants)
- Residual risk — never promise zero
Even after a negative screen, residual carrier risk persists because panels miss some pathogenic variants, rare genes are absent, and coverage is incomplete. Counseling formula conceptually:
Posterior carrier risk depends on prior (ancestry/family history) × test sensitivity for that gene.
If partner A is a known carrier and partner B screens negative for that gene with high detection rate, risk of an affected child falls substantially but is not absolute zero unless the test essentially excludes carrier status for practical purposes—still speak in residual-risk language.
- Ethnicity-based history vs universal / expanded screening
- Historical model
For decades, guidelines emphasized ethnicity-based offering (for example, Ashkenazi Jewish panels for Tay–Sachs, Canavan, familial dysautonomia; hemoglobinopathy screening by ancestry; cystic fibrosis with varying detection by ancestry). This model aimed resources at higher carrier frequencies but had problems:
- Self-reported ancestry is incomplete or mixed
- Equitable offer was inconsistent
- Many couples outside “targeted” groups still had risk
- Stigmatization and checklist medicine risks
- Contemporary direction
Professional bodies (including ACMG practice resources on prenatal/preconception carrier screening) have moved toward broader, more universal offering of expanded panels (tiered gene lists in ACMG frameworks), rather than offering only if a patient “looks” like a high-risk ethnicity. Ancestry remains relevant for:
- Interpreting detection rates and residual risk
- Adding condition-specific tests historically enriched in a group when not on a given panel
- Counseling hemoglobinopathy risks and other population genetics nuances
- Approach Strength Limitation
- Ethnicity-targeted only Higher pre-screen probability in some groups Misses mixed ancestry; equity problems
Universal expanded panel More consistent offer; finds unexpected carriers VUS/unexpected findings; variable gene inclusion; cost/access
Family-history–driven testing High yield when a familial variant known Many carriers have no family history of the AR disease
Expanded carrier screening (ECS) counseling must cover: conditions vary by lab; some conditions are variable in severity; not all childhood-lethal; partner testing strategy if one is positive; and that ECS is not a substitute for newborn screening or for diagnostic testing of a symptomatic person.
Cascade after a carrier is identified
Educate about the condition and inheritance.
Offer partner testing —preferably sequencing/analysis appropriate to the gene, not an overly limited variant panel that misses partner risk.
If both carry pathogenic variants in the same gene, discuss reproductive options (PGT, prenatal diagnosis, donor gametes, acceptance of risk)—Domain 3C detail.
Offer testing to relatives who may share carrier status when appropriate.
Somatic (tumor) testing vs germline testing
Oncology increasingly orders tumor (somatic) genomic profiling to identify therapeutic targets (for example, EGFR in lung cancer, NTRK fusions, homologous recombination repair defects relevant to PARP inhibitors). Genetic counselors must prevent category errors:
Somatic tumor testing Germline testing
Sample Tumor tissue / ctDNA Blood, saliva, cultured fibroblasts, etc.
- Primary goal Treatment selection, prognosis in cancer care Hereditary risk, cascade testing, reproductive risk
- Variant origin Acquired in tumor (usually) Constitutional, in all (or mosaic) cells
- Family implications None until a variant is shown or suspected germline Direct
VAF clues High variant allele fraction or variants in known cancer-predisposition genes may suggest germline Confirmed with germline assay
Counseling rules of thumb
A tumor report listing a BRCA1 variant is not automatically a hereditary diagnosis—confirm with germline testing when hereditary risk is possible or when guidelines recommend reflex germline evaluation.
“Germline-focused” hereditary cancer panels and tumor-only assays answer different questions; do not tell relatives to change medical care based solely on an unconfirmed tumor call.
Paired tumor–normal sequencing can help sort somatic vs germline in one workflow when available.
CHIP (clonal hematopoiesis) and mosaicism can complicate blood-based findings—another reason to interpret in oncology-genetics context.
Worked scenario
Tumor sequencing in a 42-year-old with breast cancer shows a TP53 variant. Next best genetics step: evaluate for possible Li-Fraumeni germline risk with appropriate pretest counseling and germline confirmatory testing—not cascade testing of children based on the tumor report alone.
Research testing vs clinical testing
- Dimension Clinical genetic test Research genetic test
- Purpose Patient care decision Answer a scientific question under a protocol
- Oversight CLIA clinical lab standards (U.S.) IRB/ethics board; research lab may be non-CLIA
Result return Expected as part of care May be none, summary only, or validated return via clinical confirmation
Interpretation Clinical-grade claim May be exploratory, novel gene discovery, or limited validation
Consent Clinical informed consent Research informed consent + possibly separate clinical consent if results returned
Billing Insurance/self-pay clinical pathways Usually funded by study; not a workaround for denied clinical testing without disclosure
Hard counseling line: If a patient needs a result for medical or reproductive decisions, pursue clinical testing . Research participation can be complementary (gene discovery after negative clinical exome) but should not be sold as equivalent care. When research returns a candidate finding, confirm in a clinical laboratory before medical management or cascade testing.
- Consent themes unique to research genomics
- Possibility of no personal results
- Data sharing (controlled-access databases), re-identification risks, and future recontact
- Secondary findings policies differing from ACMG clinical secondary findings menus
- Right to withdraw (data already shared may not be fully retractable)
- Whether findings will be reanalyzed over time
- Putting Domain 3B test types together
Test type Primary question
Diagnostic What explains this phenotype?
Screening (incl. NBS) Who in an asymptomatic population needs confirmatory testing?
Predictive / pre-symptomatic Will this asymptomatic person develop / be at high risk for the familial disease?
Carrier What is the reproductive risk for recessive/X-linked disease?
Somatic What tumor variants guide cancer therapy?
Research What can we learn under a protocol—and are results clinically confirmable?
Board stems often mix two categories (tumor finding → germline counseling; ECS positive → partner testing; research candidate variant → clinical confirmation). Name the category first, then choose the next step.
- Exam traps
- Telling an AR carrier they “have the disease.”
Claiming negative ECS means zero risk of an affected child.
Cascading relatives from tumor-only variants without germline confirmation.
Using a research study as the only pathway for urgent clinical management decisions without explaining limitations.
Offering ethnicity-only screening and refusing ECS discussion solely based on appearance.
Practice checkpoints
Explain residual risk after negative carrier screening.
Contrast ethnicity-targeted vs universal expanded offering.
Separate somatic tumor results from germline cascade implications.
State when research findings require clinical confirmation.